In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations

International Journal of Pharmaceutics

Volumn 428, Issue 1-2, 2012, Pages 8-17

  Thombre, Avinash G ^a   Shah, Jaymin C ^a   Sagawa, Kazuko ^a   Caldwell, W Brett ^b  

^a PFIZER INC   (United States)

^b Bend Research Incorporated   (United States)

Author keywords

Bioavailability enhancement; Cyclodextrin; Nanosuspension; Solubilization; Ziprasidone

Indexed keywords

CYCLODEXTRIN; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; ZIPRASIDONE;

ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG ABSORPTION; DRUG FORMULATION; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SOLUBILIZATION; SPRAY DRYING;

ABSORPTION; ACETATES; ANIMALS; ANTIPSYCHOTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DOGS; DRUG STABILITY; FASTING; MALE; METHYLCELLULOSE; NANOPARTICLES; PARTICLE SIZE; PIPERAZINES; SOLUBILITY; SUCCINIC ACID; SUSPENSIONS; THIAZOLES;

EID: 84859430848     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.02.004     Document Type: Article

References (41)

1. N.J. Babu, and A. Nangia Solubility advantage of amorphous drugs and pharmaceutical cocrystals Cryst. Growth Des. 11 2011 2662 2679
2. M. Bernardo, J.R. Azanza, C. Rubio-Terres, and J. Rejas Cost-effectiveness analysis of schizophrenia relapse prevention: an economic evaluation of the ZEUS (ziprasidone-extended-use-in-schizophrenia) study in Spanish Clin. Drug Invest. 26 2006 447 457
3. M. Bernardo, J.R. Azanza, C. Rubio-Terres, and J. Rejas Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study ziprasidone extended use in schizophrenia (ZEUS) Actas Esp. Psiquiatr. 35 2007 259 262
4. J. Bobes, F. Canas, J. Rejas, and J. Mackell Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain Prog. Neuropsychopharmacol. Biol. Psychiatry 28 2004 1287 1297 (Pubitemid 39592926)
5. M.E. Brewster, and T. Loftsson Cyclodextrins as pharmaceutical solubilizers Adv. Drug Deliv. Rev. 59 2007 645 666 (Pubitemid 47299263)
6. Curatolo, W.J., Herbig, S.M., Thombre, A.G., Shah, J.C., Shamblin, S.L., Lukas, T., Caldwell, W.B., Friesen, D.T., Lyon, D.K., Craig, C.D., 2009. Methods, dosage forms, and kits for administering ziprasidone without food. (Pfizer Inc., USA). Application: WO 2009109844 A1.
7. D.G. Daniel Tolerability of ziprasidone: an expanding perspective J. Clin. Psychiatry 64 2003 40 49
8. D. Fleisher, R. Bong, and B.H. Stewart Improved oral drug delivery: solubility limitations overcome by the use of prodrugs Adv. Drug Deliv. Rev. 19 1996 115 130 (Pubitemid 26192965)
9. D.T. Friesen, R. Shanker, M. Crew, D.T. Smithey, W.J. Curatolo, and J.A.S. Nightingale Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview Mol. Pharm. 5 2008 1003 1019
10. K. Gandelman, J.A. Alderman, P. Glue, I. Lombardo, R.R. La Badie, M. Versavel, and S.H. Preskorn The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial J. Clin. Psychiatry (Memphis, TN, United States) 70 2009 58 62
11. ® [U.S. Prescribing Information including Patient Summary of Information], Pfizer Inc., Revised 2009.
12. W.M. Greenberg, and L. Citrome Ziprasidone for schizophrenia and bipolar disorder: a review of the Clinical trials CNS Drug Rev. 13 2007 137 177 (Pubitemid 47052346)
13. B.A. Hamelin, S. Allard, L. Laplante, J. Miceli, K.D. Wilner, J. Tremblay, and M. Lebel The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone Pharmacotherapy 18 1998 9 15 (Pubitemid 28058997)
14. T.S. Harrison, and L.J. Scott Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder CNS Drugs 20 2006 1027 1052 (Pubitemid 44920139)
15. D.J. Hauss Oral lipid-based formulations Adv. Drug Deliv. Rev. 59 2007 667 676 (Pubitemid 47285409)
16. J. Hong, J.C. Shah, and M.D. McGonagle Effect of cyclodextrin derivation and amorphous state of complex on accelerated degradation of ziprasidone J. Pharm. Sci. 100 2011 2703 2716
17. A.J. Humberstone, and W.N. Charman Lipid-based vehicles for the oral delivery of poorly water soluble drugs Adv. Drug Deliv. Rev. 25 1997 103 128
18. J.S. Janiszewski, H.G. Fouda, and R.O. Cole Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography J. Chromatogr. B: Biomed. Appl. 668 1995 133 139
19. J.-U.A.H. Junghanns, and R.H. Mueller Nanocrystal technology, drug delivery and clinical applications Int. J. Nanomed. 3 2008 295 309
20. F. Kesisoglou, S. Panmai, and Y. Wu Nanosizing - oral formulation development and biopharmaceutical evaluation Adv. Drug Deliv. Rev. 59 2007 631 644 (Pubitemid 47285408)
21. Y. Kim, D.A. Oksanen, W. Massefski Jr., J.F. Blake, E.M. Duffy, and B. Chrunyk Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether J. Pharm. Sci. 87 1998 1560 1567 (Pubitemid 28559642)
22. J. Lincoln, E. Stewart Mark, and H. Preskorn Sheldon How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone J. Psychiatr. Pract. 16 2010 103 114
23. A. Melander Influence of food on the bioavailability of drugs Clin. Pharmacokinet. 3 1978 337 351 (Pubitemid 9013897)
24. E. Merisko-Liversidge, G.G. Liversidge, and E.R. Cooper Nanosizing: a formulation approach for poorly-water-soluble compounds Eur. J. Pharm. Sci. 18 2003 113 120 (Pubitemid 36184748)
25. J.J. Miceli, K.D. Wilner, R.A. Hansen, A.C. Johnson, G. Apseloff, and N. Gerber Single- and multiple-dose pharmacokinetics of ziprasidone under nonfasting conditions in healthy male volunteers Br. J. Clin. Pharmacol. 49 2000 5S 13S (Pubitemid 30151047)
26. N.C. Patel, and P.E. Keck Jr. Ziprasidone: efficacy and safety in patients with bipolar disorder Expert Rev. Neurotherapeutics 6 2006 1129 1138 (Pubitemid 44231971)
27. D.O. Perkins Predictors of noncompliance in patients with schizophrenia J. Clin. Psychiatry 63 2002 1121 1128 (Pubitemid 36084056)
28. C.J.H. Porter, C.W. Pouton, J.F. Cuine, and W.N. Charman Enhancing intestinal drug solubilization using lipid-based delivery systems Adv. Drug Deliv. Rev. 60 2008 673 691
29. L.E. Schmidt, and K. Dalhoff Food-drug interactions Drugs 62 2002 1481 1502 (Pubitemid 34804156)
30. A.T.M. Serajuddin Salt formation to improve drug solubility Adv. Drug Deliv. Rev. 59 2007 603 616 (Pubitemid 47285406)
31. Shah, J.C., Shah, P.S., Wisniecki, P., Wagner, D.R., 2008. Injectable depot formulations and methods for providing sustained release of nanoparticle compositions. (Pfizer Inc., USA). Application: US 20080305161 A1.
32. B.N. Singh Effects of food on clinical pharmacokinetics Clin. Pharmacokinet. 37 1999 213 255 (Pubitemid 29452756)
33. B.N. Singh, and B.K. Malhotra Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy Clin. Pharmacokinet. 43 2004 1127 1156 (Pubitemid 40013180)
34. S.M. Stahl, and D.K. Shayegan The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice J. Clin. Psychiatry 64 2003 6 12
35. V.J. Stella, and K.W. Nti-Addae Prodrug strategies to overcome poor water solubility Adv. Drug Deliv. Rev. 59 2007 677 694 (Pubitemid 47285410)
36. J.-l. Tang, J. Sun, and Z.-G. He Self-emulsifying drug delivery systems: strategy for improving oral delivery of poorly soluble drugs Curr. Drug Ther. 2 2007 85 93 (Pubitemid 46723141)
37. A.G. Thombre, S.M. Herbig, and J.A. Alderman Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect Pharm. Res. 28 2011 3159 3170
38. R.D. Toothaker, and P.G. Welling The effect of food on drug bioavailability Annu. Rev. Pharmacool. Toxicol. 20 1980 173 199
39. Y.N. Usha, T.T. Angel, and N. Udupa Nanotechnology: perspectives on solubility/bioavailability enhancement Pharma Rev. 8 2010 59 66
40. P.G. Welling Effects of food on drug absorption Annu. Rev. Nutr. 16 1996 383 415
41. L. Zimbroff Dan, H. Allen Michael, J. Battaglia, L. Citrome, A. Fishkind, A. Francis, L. Herr Daniel, D. Hughes, M. Martel, H. Preval, and R. Ross Best clinical practice with ziprasidone IM: update after 2 years of experience CNS Spectr. 10 2005 1 15 (Pubitemid 41443046)